Organic compounds -- part of the class 532-570 series – Organic compounds – Sulfur containing
Reexamination Certificate
2007-05-08
2007-05-08
Aulakh, Charanjit S. (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Sulfur containing
C568S043000, C568S064000, C568S308000, C568S417000
Reexamination Certificate
active
10442191
ABSTRACT:
Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-chalcogenmethylcarbonyl group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or for stimulating hematopoietic cells ex vivo.
REFERENCES:
patent: 3875232 (1975-04-01), Magee
patent: 4966721 (1990-10-01), Farng et al.
patent: 5075482 (1991-12-01), Seltzer et al.
patent: 5523495 (1996-06-01), Oda et al.
patent: 5601699 (1997-02-01), Degnan et al.
patent: 5859052 (1999-01-01), Nugent et al.
patent: 5877329 (1999-03-01), Chen et al.
patent: 5908868 (1999-06-01), Buck et al.
patent: 5925644 (1999-07-01), Jakobi et al.
patent: 5965719 (1999-10-01), Hindsgaul
patent: 5981580 (1999-11-01), Nugent et al.
patent: 6071923 (2000-06-01), Nudelman et al.
patent: 6118001 (2000-09-01), Owen et al.
patent: 6133296 (2000-10-01), Lieb et al.
patent: 6150567 (2000-11-01), Sugawa et al.
patent: 6235717 (2001-05-01), Leban et al.
patent: 6255342 (2001-07-01), Lieb et al.
patent: 6495719 (2002-12-01), Lan-Hargest et al.
patent: 2003/0153465 (2003-08-01), Schallner et al.
patent: 734489 (1998-12-01), None
patent: 764182 (2000-11-01), None
patent: 42298 (1984-09-01), None
patent: 622672 (1994-11-01), None
patent: 1148102 (2001-10-01), None
patent: 1273571 (2003-08-01), None
patent: WO98/22444 (1998-05-01), None
patent: WO00/00469 (2000-01-01), None
patent: WO00/66557 (2000-11-01), None
patent: WO01/36354 (2001-05-01), None
patent: WO01/70675 (2001-09-01), None
Collins et al., “Oral Sodium Phenylbutyrate Therapy in Homozygous β Thalassemia: A Clinical Trial,” Blood, 85(1), 1995, 43-49.
Denney et al., “Preparation and Reactions of Some Phosphobetaines,” J. Org. Chem., 27, 1962, 3404-3408.
Fruehauf et al., “Use of the Extreme Drug Resistance Assay to Evaluate Mechanisms of Resistance in Ovarian Cancer: Taxol Resistance and MDR-1 Expression,” Chemosensitivity Testing in Gyneologic Malignancies and Breast Cancer, 19, 1994, 39-52.
Grunstein, “Histoneactylation in chromatin structure and transcription,” Nature, 389, 1997, 349-352.
Hoffmann et al., “A non-isotopic assay for histone deacetylase activity,” Nucleic Acids Research, 27 (9), 1999, 2057-2058.
Kano et al., “New Synthetic Design for Formation of Carbon-Carbon Triple Bonds,” J. Org. Chem., 43 (22), 1978, 4366-4367.
Kolle et al., “Biochemical Methods for Analysis of Histone Deacetylases, ” METHODS: A Comparison to Methods in Enzymology, 15, 1998, 323-331.
Lebedev et al., “Acylation of Cyclopropyl-Substituted Alkenes with Complexes Formed by ω-(Ethylthio)alkanol Flourides and Boron Trifluoride,” Russian Journal of Organic Chemistry, 37(3), 2001, 326-333.
Magdesieva et al., Zh. Org. Khim, 17(2), 1981, 340-342.
Marks et al., “Histone deacetylase inhibitors; inducers of differentiation of apoptosis of transformed cells,” (Database Caplus, Accession No. 2000:598231), Journal of the National Cancer Institute, 92(15), 2000, 1210-1216.
Moser et al., “Measurement of Saturated Very Long Chain Fatty Acids in Plasma,” Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual, 1991, 177-191.
Panyim et al., “High Resolution Acrylamide Gel Electrophoresis of Histones,” Archives of Biochemistry and Biophysics, 130, 1969, 337-346.
Parameswara et al., “One-Step Vilsmeier Route to Some 5-Aryl-3-methyl-2(E), 4(E)-pentadienals and thier Oxidation to Penta-dienoic Acids,” Synthesis, 1980, 815-818.
Pazin et al., “What's Up and Down with Histone Deacetylation and Transcription?,” Cell, 89, 1997, 325-328.
Steffan et al., “Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosphila,” Nature, 413, 2001, 739-743.
Steinberg, “The acetylation state of nuclear proteins could be one key to pathology and treatment,” The Scientist, 16 (2), 2002, 34.
Taguchi et al., “A New Method for the Synthesis of 3-Alkylfuran and 2, 4-Dialkylfuran,” Chemistry Letters, 8, 1975, 853-854.
Trager et al., “Human Malaria Parasites in Continuous Culture,” Science, 193, 1976, 673-675.
Wade et al., “Histone acetylation: chromatin in action,” Trends Biochem. Sci., 22, 1997, 128-132.
Watkins et al., “Peroxisomal Fatty Acid β-Oxidation in HepG2 Cells,” Archives of Biochemistry and Biophysics, 289 (2), 1991, 329-336.
Wolffe, “Histone Deacetylase: A Regulator of Transcription,” Science, 272, 1996, 371-372.
E. Corey et al., “t-butoxymethyllithium: direct preparation from t-butyl-methyl ether and applications as hydroxymethyl anion equivalent.”Tetrahedron Letters. vol. 24, No. 31, 1983, p. 3165-3168.
Carreira et al., “Catalytic, Enantioselective Acetone Aldol Additions with 2-methoxypropene.”Journal of the American Chemical Society, American Chemical Society, Washington DC, (1995) p. 3649-3650.
Kaufman Robert J.
Lan-Hargest Hsuan-Yin
Aulakh Charanjit S.
Errant Gene Therapeutics, LLC
Steptoe & Johnson LLP
LandOfFree
Histone deacetylase inhibitors based on... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histone deacetylase inhibitors based on..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histone deacetylase inhibitors based on... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3823603